ArticleCerebral circulation - cognition and behavior2022
What does aducanumab treatment of Alzheimer's disease mean for research on vascular cognitive disorders?
Article in Cerebral circulation - cognition and behavior, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 10 citations in OpenAlex.
- The vascular contribution to dementia: World Stroke Organization scientific statement.International journal of stroke : official journal of the International Stroke Society · 2026Review
- Cerebral Small Vessel Disease, Hypertension, and Vascular Contributions to Cognitive Impairment and Dementia.Hypertension (Dallas, Tex. : 1979) · 2024Review
- The impending era of beta-amyloid therapy: Clinical and research considerations for treating vascular contributions to neurodegeneration.Cerebral circulation - cognition and behavior · 2024Article
- The promise of molecular science in brain health. What breakthroughs are anticipated in the next 20 years?Cerebral circulation - cognition and behavior · 2024Article
- Editorial.Cerebral circulation - cognition and behavior · 2024Article
- VasCog 2023: 20 years of research on vascular behavioural and cognitive disorders.Cerebral circulation - cognition and behavior · 2024Article
- Advances in the Study of the Pathology and Treatment of Alzheimer's Disease and Its Association with Periodontitis.Life (Basel, Switzerland) · 2023Review
- Advances in Stroke: Brain Health in 2023.Stroke · 2023Article
- Metformin mitigates amyloid βMetabolic brain disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 17 institutions in 12 countries.
Funding
Abstract
•Controversial registration of aducanumab for Alzheimer's Disease•Aducanumab is the subject of post-licensing observational studies aiming to follow the effects of the drug•Given the high prevalence of cerebrovascular pathology it is important that these studies do not ignore vascular cognitive disorders•The studies may give detailed phenotyping data that may lead to knowledge of targets for treatments of patients with vascular cognitive disorders.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.